靶向ELK-1信号转导的抗抑郁效应
该研究基于抑郁自杀者死后海马组织与抑郁个体血样,发现ELK1 mRNA在海马中上调、外周血ELK1表达未下降与治疗抵抗相关。小鼠海马过表达ELK-1本身即可产生抑郁行为,选择性抑制ELK-1激活可阻止应激诱导的抑郁样分子、可塑性与行为状态,提示ELK-1是ERK下游可独立靶向的抑郁相关信号模块。
要点
- 抑郁自杀者海马ELK1 mRNA上调,提示ELK-1参与抑郁病理
- 抑郁个体血中ELK1表达未下降与治疗抵抗相关
- 选择性抑制ELK-1激活可阻止应激所致抑郁样状态,且可独立于ERK靶向
核心结论
- ELK-1是ERK下游与抑郁病理和治疗相关的特异性信号模块,可独立于ERK被靶向,为信号转导类抗抑郁药提供可成药性概念验证。
研究设计与样本
- 研究采用抑郁自杀者死后海马组织与抑郁个体血样进行表达分析,并在小鼠中开展海马ELK-1过表达与选择性抑制ELK-1激活的实验。
主要发现
- 抑郁自杀者海马组织中ELK1 mRNA上调。
- 抑郁个体血样中ELK1表达未下降与治疗抵抗相关。
- 小鼠海马过表达ELK-1本身即产生抑郁行为。
- 选择性抑制ELK-1激活可阻止应激诱导的抑郁样分子、可塑性与行为状态。
临床怎么用
- 提示ELK-1可作为抑郁相关信号转导靶点,支持开发不依赖ERK的选择性ELK-1抑制策略。
- 血样ELK1表达变化可能作为治疗抵抗的相关标志,但需进一步验证。
局限性
- 研究对象包括人类死后海马组织、外周血样与小鼠模型,结论外推至临床抗抑郁疗效仍需更多研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Depression, a devastating psychiatric disorder, is a leading cause of disability worldwide. Current antidepressants address specific symptoms of the disease, but there is vast room for improvement 1 . In this respect, new compounds that act beyond classical antidepressants to target signal transduction pathways governing synaptic plasticity and cellular resilience are highly warranted2-4. The extracellular signal-regulated kinase (ERK) pathway is implicated in mood regulation5-7, but its pleiotropic functions and lack of target specificity prohibit optimal drug development. Here, we identified the transcription factor ELK-1, an ERK downstream partner 8 , as a specific signaling module in the pathophysiology and treatment of depression that can be targeted independently of ERK. ELK1 mRNA was upregulated in postmortem hippocampal tissues from depressed suicides; in blood samples from depressed individuals, failure to reduce ELK1 expression was associated with resistance to treatment. In mice, hippocampal ELK-1 overexpression per se produced depressive behaviors; conversely, the selective inhibition of ELK-1 activation prevented depression-like molecular, plasticity and behavioral states induced by stress. Our work stresses the importance of target selectivity for a successful approach for signal-transduction-based antidepressants, singles out ELK-1 as a depression-relevant transducer downstream of ERK and brings proof-of-concept evidence for the druggability of ELK-1.
引用
- Apazoglou K, Farley S, Gorgievski V, et al. Antidepressive effects of targeting ELK-1 signal transduction. Nat Med. 2018. PMID: 29736027. doi:10.1038/s41591-018-0011-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。